ריבון 35
unipharm ltd, israel - risedronic acid - טבליה - risedronic acid 35 mg - risedronic acid - risedronic acid - treatment of postmenopausal osteoporosis to reduce the risk of vertebral fractures. treatment of established postmenopausal osteoporosis to reduce the risk of hip fractures. prevention of osteoporosis in postmenopausal women with increased risk of osteoporosis. treatment of osteoporosis in men at high risk of fracture.
אקלסטה
novartis israel ltd - zoledronic acid - תמיסה לאינפוזיה - zoledronic acid 5 mg / 100 ml - zoledronic acid
אלנדרונט טבע 10 מג
teva pharmaceutical industries ltd, israel - alendronic acid as monohydrate - טבליה - alendronic acid as monohydrate 10 mg - alendronic acid
מקסיבון 70
unipharm ltd, israel - alendronate as sodium - טבליה - alendronate as sodium 70 mg - alendronic acid
ריבון 35
unipharm ltd, israel - risedronic acid - טבליה - risedronic acid 35 mg - risedronic acid
זולדרוניק אסיד תרו 4 מג5 מל
taro international ltd, israel - zoledronic acid - תרכיז להכנת תמיסה לאינפוזיה - zoledronic acid 4 mg / 5 ml - zoledronic acid
זולדרוניק אסיד הוספירה 4 מג 5 מל
pfizer pfe pharmaceuticals israel ltd - zoledronic acid - תרכיז להכנת תמיסה לאינפוזיה - zoledronic acid 4 mg / 5 ml - zoledronic acid
זולדרוניק דקסל 4 מג 5 מל
dexcel ltd, israel - zoledronic acid - תרכיז להכנת תמיסה לאינפוזיה - zoledronic acid 4 mg / 5 ml - zoledronic acid
זולדרוניק טבע 4 מ"ג/5 מ"ל
abic marketing ltd - zoledronic acid as monohydrate 4 mg/vial - concentrate for solution for infusion - zoledronic acid - treatment of hypercalcaemia of malignancy. treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors , in conjunction with standard antineoplastic therapy. prostate cancer should have progressed after treatment with at least one hormonal therapy.
זולדרוניק טבע 4 מ"ג/5 מ"ל
abic marketing ltd - zoledronic acid as monohydrate 4 mg/vial - concentrate for solution for infusion - zoledronic acid - treatment of hypercalcaemia of malignancy. treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors , in conjunction with standard antineoplastic therapy. prostate cancer should have progressed after treatment with at least one hormonal therapy.